Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM01

Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Adverse Events, Chemotherapy, Oncology Pharmacy Programs

Presenters: Megan May, PharmD, BCOP, Clinical Oncology Pharmacy Specialist, Baptist Health Lexington, Lexington, KY; and Jeannie Patrick, PharmD, BCOP, Clinical Oncology Pharmacy Specialist, Baptist Health Lexington, Lexington, KY

Co-Author: Macy Pike, PharmD, BCPS, Baptist Health Lexington, Lexington, KY

Background: In 2019, the US Census Bureau reported that 27.5 million people (8.5% of the US population) did not have insurance in 2018.1 The estimated out-of-pocket (OOP) spending on orally administered anticancer agents for Medicare Part D beneficiaries increased from 2010 to 2019, with a mean 12-month OOP spending of $8794 in 2010 versus $10,470 in 2019.2 As a result of unmanageable OOP prescription costs, patients may experience delays in initiation of treatment or abandon oral anticancer treatment.3 In 2017, Baptist Health Lexington established an oral chemotherapy clinic, staffed with a full-time oncology-trained pharmacist and a financial navigator to assist with the acquisition and dissemination of oral anticancer drugs.

Objectives: The primary end point was to describe the incidence of treatment abandonment and delay in an oral chemotherapy clinic designed to minimize these problems at an outpatient cancer care center. Secondary end points included an analysis of patients who abandoned their prescription to initiate alternate treatment, patient’s initial OOP prescription cost, and length of days to dispense medications.

Methods: This was a retrospective cohort analysis of all patients (N = 150) enrolled in the oral chemotherapy clinic who had a new prescription for oral anticancer agents that were prescribed between August 1, 2017, and January 31, 2018. Descriptive statistics were used to evaluate the incidence of treatment abandonment and delay, given the pilot nature of this study and its small sample size.

Results: The incidence of treatment abandonment and delay was low, at 8.7% (N = 13) and 2.7% (N = 4), respectively. Of the 13 participants who abandoned treatment, 5 (38.5%) participants opted for hospice care, 4 (30.8%) participants declined further treatment, 3 (23.1%) participants were transitioned to an alternative intravenous option within the same therapeutic class, and 1 participant opted to pursue a holistic approach with an outside provider. Small differences occurred related to treatment abandonment, with greater initial OOP costs (11%, >$2000 OOP; 8%, <$2000 OOP). The average time from submission of the oral anticancer agent prescription to dispense of the medication was 6.7 days.

Conclusion: These findings suggest that the incidence of treatment abandonment and delay with oral anticancer agents is low when patients have readily available access to services that provide financial assistance. Access to a pharmacist and a financial navigator may improve patient outcomes by reducing treatment abandonment and delay.

  1. Berchick ER, Barnett JC, Upton RD. Health Insurance Coverage in the United States: 2018. Current Population Reports P60-267 (RV); November 8, 2019. www.census.gov/library/publications/2019/demo/p60-267.html. Accessed September 15, 2020.
  2. Dusetzina SB, Huskamp HA, Keating NL. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019. JAMA. 2019;321:2025-2027. Erratum in: JAMA. 2019;322:174.
  3. Doshi JA, Li P, Huo H, et al. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J Clin Oncol. 2018;36:476-482.
Related Items
Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer
Sonya K. Kedzior, PharmD, YoungYoon Ham, PharmD, Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in Review Article, Adverse Events, Antibiotics, Drug Resistance
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.